Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GPR39 | O43194 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CDC7 | O00311 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570899 | 0.77 | CTSK (0.52) | CTSKKDM4EGPR39GAACDC7 | |
| SCHEMBL3566343 | 0.76 | CTSK (0.54) | CTSKKDM4EGPR39GAACDC7 | |
| SCHEMBL13572330 | 0.76 | GPR39 (0.44) | CTSKKDM4EALDH1A1GPR39GAA | |
| SCHEMBL5429300 | 0.72 | SLC6A2 (0.48) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL13572064 | 0.72 | CTSK (0.45) | CTSKKDM4EGAA | |
| SCHEMBL3574026 | 0.70 | CTSK (0.42) | CTSKKDM4EALDH1A1GPR39GAA | |
| SCHEMBL3571502 | 0.70 | CTSK (0.44) | CTSKKDM4EGPR39GAA | |
| SCHEMBL16548498 | 0.68 | ALDH1A1 (0.58) | CTSKKDM4EALDH1A1L3MBTL1GPR39 | |
| SCHEMBL18672959 | 0.68 | MEN1 (0.53) | MEN1KMT2AKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL1579641 | 0.67 | KDM4E (0.60) | CTSKKDM4EALDH1A1L3MBTL1GPR39 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633363-B1 | PYRIDINYL ACETONITRILES | MERCK SERONO SA (CH) | 2012-11-07 | — | — | EP | claimed |
| US-7855212-B2 | Pyridinyl acetonitriles | MERCK SERONO SA (CH) | 2010-12-21 | — | — | US | claimed |
| US-20070060594-A1 | Pyridinyl acetonitriles | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2007-03-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060594-A1 | Pyridinyl acetonitriles | GSK3B, GSK3A, MAPK3 | MEN1 3686/4885KMT2A 4507/4885CTSK 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.